Winner of the 2006 Medical Design Excellence Award for General Hospital Devices and Therapeutic Products; Winner of the Gold Industrial Design Excellence Award (IDEA) from the Industrial Designers Society of America (IDSA) during the IDSA's 2006 competition. Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.
Insulet Launches New Omnipod Podder Community Platform. Insulet Announces Development Partner for the OmniPod Artificial Pancreas. Insulet Enters into Development Agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated Insulin. nsulet Corporation to Assume Distribution Rights for OmniPod(R) System in Canada. Insulet Extends Exclusive Agreement for Blood Glucose Monitoring.
|Key Personnel: Patrick Sullivan, president & CEO; Aiman Abdel-Malek, SVP, IT; Charles Alpuche, SVP & COO; Bret Christensen, SVP & chief commercial officer; David Colleran, SVP, general counsel; Deborah Gordon, SVP, communications; Michael Levitz, SVP & CFO; Dr. Trang Ly, VP & medical director; Shacey Petrovic, EVP, diabetes products; Michael Spears, SVP, quality management; Brad Thomas, EVP, HR;|
600 Technology Park